Medications for Eosinophilic Granulomatosis With Polyangiitis

2 results

  • fasenra

    (Benralizumab)
    AstraZeneca Pharmaceuticals LP
    FASENRA is indicated for the add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype and for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It is not for acute bronchospasm relief.

  • nucala

    (mepolizumab)
    GlaxoSmithKline LLC
    NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.